{"id":11115,"date":"2025-08-11T15:31:16","date_gmt":"2025-08-11T10:31:16","guid":{"rendered":"https:\/\/ksestocks.com\/blog\/?p=11115"},"modified":"2025-08-11T15:31:19","modified_gmt":"2025-08-11T10:31:19","slug":"agp-limited-profits-surge-in-second-quarter-of-2025","status":"publish","type":"post","link":"https:\/\/ksestocks.com\/blog\/agp-limited-profits-surge-in-second-quarter-of-2025\/","title":{"rendered":"AGP Limited: Profits Surge in Second Quarter of 2025"},"content":{"rendered":"\n<p><strong>AGP Limited (<a href=\"https:\/\/ksestocks.com\/blog\/tag\/agp\/\" data-type=\"post_tag\" data-id=\"200\" target=\"_blank\" rel=\"noreferrer noopener\">AGP<\/a>)<\/strong>, one of Pakistan\u2019s major pharmaceutical companies, is set to announce impressive results for the second quarter of 2025 (April\u2013June). The company\u2019s earnings are expected to more than double compared to the same period last year, showing strong performance despite a seasonal dip in sales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Earnings growth<\/h2>\n\n\n\n<p>Profit after tax (PAT) is expected to reach <strong>PKR 968 million<\/strong>, which is around <strong>1.5 times higher<\/strong> than last year\u2019s PKR 391 million for the same quarter. This translates to an earnings per share (EPS) of <strong>PKR 2.79<\/strong>, up from PKR 1.36 a year ago.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Revenue performance<\/h2>\n\n\n\n<p>Sales are projected at <strong>PKR 6.9 billion<\/strong>, up <strong>20% year-on-year<\/strong>. This growth comes from higher sales volumes, the deregulation of non-essential medicines (allowing for flexible pricing), and price increases for several essential medicines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Seasonal slowdown<\/h2>\n\n\n\n<p>While revenue is strong compared to last year, it is expected to be <strong>4% lower than the previous quarter<\/strong>. This is largely due to seasonal factors, as certain medicines see reduced demand during this time of the year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Improved margins<\/h2>\n\n\n\n<p>Gross profit margins are expected to improve to <strong>57%<\/strong>, compared to 55% in the same quarter last year. The increase is mainly due to higher drug prices, although margins have remained flat compared to the previous quarter as lower sales volumes offset pricing gains.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Lower finance costs<\/h2>\n\n\n\n<p>AGP is also benefiting from reduced borrowing costs. Finance expenses are expected to drop <strong>52% year-on-year<\/strong>, thanks to lower interest rates, which further supports overall profitability.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Half-year snapshot<\/h2>\n\n\n\n<p>For the first half of 2025, AGP\u2019s profit is expected to reach <strong>PKR 2.03 billion<\/strong>, up <strong>40% from the same period in 2024<\/strong>. The growth reflects strong pricing power, healthy sales, and cost savings from lower interest expenses.<\/p>\n\n\n\n<p>AGP\u2019s second-quarter results show the strength of its business model. Even with seasonal sales dips, the combination of higher prices, strong margins, and lower finance costs has driven significant earnings growth. With continued demand for its medicines and a stronger financial position, AGP is on track for a solid year.<\/p>\n\n\n\n<p><strong>Source: Taurus Securities Limited <\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AGP Limited (AGP), one of Pakistan\u2019s major pharmaceutical companies, is set to announce impressive results for the second quarter of 2025 (April\u2013June).<\/p>\n","protected":false},"author":9252,"featured_media":6468,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[154,138],"tags":[200],"class_list":["post-11115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-financials","tag-agp"],"featured_image_src":{"landsacpe":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/AGP-STOCK-PSX-1140x445.png",1140,445,true],"list":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/AGP-STOCK-PSX-463x348.png",463,348,true],"medium":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/AGP-STOCK-PSX-300x188.png",300,188,true],"full":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/AGP-STOCK-PSX.png",1920,1200,false]},"_links":{"self":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/11115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/users\/9252"}],"replies":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/comments?post=11115"}],"version-history":[{"count":1,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/11115\/revisions"}],"predecessor-version":[{"id":11116,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/11115\/revisions\/11116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media\/6468"}],"wp:attachment":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media?parent=11115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/categories?post=11115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/tags?post=11115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}